Clinical Trial Results

ThermoBreast - Non-contact Breast Cancer Imaging Using AI-enhanced Thermography.

NAINTERVENTIONAL Heidelberg

RECRUITING

ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors

PHASE1, PHASE2INTERVENTIONAL Stanford, California +4 more

RECRUITING

RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive

PHASE2, PHASE3INTERVENTIONAL Huntsville, Alabama +4 more

RECRUITING

Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer

PHASE3INTERVENTIONAL Gilbert, Arizona +4 more

RECRUITING

START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer

PHASE1INTERVENTIONAL Frankfurt +4 more

RECRUITING

Met Non Small Cell Cancer Registry (MOMENT)

N/AOBSERVATIONAL Fort Lauderdale, Florida +4 more

RECRUITING

Genomics Guided Targeted Post-neoadjuvant Therapy in Patients With Early Breast Cancer (COGNITION-GUIDE)

PHASE2INTERVENTIONAL Heidelberg, Baden-Wurttemberg +4 more

RECRUITING

Personalised Neoantigen-targeting Cancer Vaccine NECVAX-NEO1 in Neoadjuvant Triple-negative Breast Cancer

PHASE1, PHASE2INTERVENTIONAL Erlangen +1 more

RECRUITING

Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors

PHASE1, PHASE2INTERVENTIONAL Los Angeles, California +4 more

RECRUITING

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

PHASE1, PHASE2INTERVENTIONAL Irvine, California +4 more

RECRUITING

CATCH: Implementation of Genomics-guided Precision Medicine in Metastatic Breast Cancer

N/AOBSERVATIONAL Augsburg +4 more

RECRUITING

A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy

PHASE3INTERVENTIONAL Greenbrae, California +4 more

RECRUITING

COGNITION: Genomics-Guided Precision Oncology in Early High-Risk Breast Cancer

N/AOBSERVATIONAL Augsburg +4 more

RECRUITING

Influence of Sarcopenia on the Course of the Diseases

N/AOBSERVATIONAL Mainz, Rhineland-Palatinate

RECRUITING

Discontinuation of CDK4/6 Inhibitors in Patients With Metastatic HR Positive, HER2 Negative Breast Cancer

PHASE2INTERVENTIONAL Berlin +4 more

RECRUITING

Phase IIIb Study of Ribociclib + ET in Early Breast Cancer

PHASE3INTERVENTIONAL Birmingham, Alabama +4 more

RECRUITING